Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer
European Urology Focus · 2026-05
DOI: 10.1016/j.euf.2026.04.018 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift European Urology Focus, 2026-05. Verfasst von Bram De Laere und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Human Structure and Repair Ghent Univer…. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Swedish Cancer Society, Kom op tegen kanker, Swedish Research Council.
Abstract (Originalsprache)
Prostate Biomarkers trial in metastatic hormone-sensitive prostate cancer (mHSPC) tests whether circulating tumor deoxyribonucleic acid (ctDNA) can personalize first-line treatment for mHSPC by safely de-escalating therapy in patients with undetectable ctDNA and by intensifying biomarker-matched treatment in ctDNA-detectable disease, aiming to preserve outcomes while reducing toxicity and improving quality of life.
Autor:innen und Institutionen
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Human Structure and Repair Ghent University, Ghent, Belgium.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Universitätsspital Zürich, Zürich, Switzerland.
- Cancer Treatment Centre, Sorlandet Hospital, Kristiansand, Norway.
- Urological Research Unit, Department of Urology, Center for Cancer and Organ Diseases Copenhagen University Hospital - Rigshospitalet, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denm…
- Research Program in Systems Oncology, Research Programs Unit and iCAN-Digital Precision Cancer Medicine Flagship, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Urology, Helsinki Universit…
Förderung
- Swedish Cancer Society
- Kom op tegen kanker
- Swedish Research Council
- Swiss Cancer League
- Bayer
- Giuliana and Giorgio Stefanini Foundation
- Swiss Cancer Foundation
- Johnson and Johnson
Zitieren
APA
De Laere, B., Crippa, A., Discacciati, A., Mortezavi, A., Müller, C., Røder, A., Rannikko, A., Ost, P., Eklund, M., Lindberg, J., Grönberg, H., & ProBio Investigators (2026). Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2026.04.018
Vancouver
De Laere B, Crippa A, Discacciati A, Mortezavi A, Müller C, Røder A, et al. Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer. European Urology Focus. 2026. doi:10.1016/j.euf.2026.04.018
BibTeX
@article{DeLaere2026,
author = {De Laere, Bram and Crippa, Alessio and Discacciati, Andrea and Mortezavi, Ashkan and Müller, Christoph and Røder, Andreas and Rannikko, Antti and Ost, Piet and Eklund, Martin and Lindberg, Johan and Grönberg, Henrik and ProBio Investigators, ProBio Investigators},
title = {Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer},
journal = {European Urology Focus},
year = {2026},
doi = {10.1016/j.euf.2026.04.018}
}
EUVIMED